The global Nicotinamide (Vitamin B3) market saw a strong recovery in August 2025 after months of decline, driven by strategic inventory reassessment and renewed demand across pharmaceuticals, nutraceuticals, and personal care sectors. Oversupply earlier in the year had led to reduced offtake, but buyers have returned with fresh procurement strategies aligned with new production cycles. Seasonal anticipation and awareness campaigns by institutions like NIH have further supported demand. European R&D activity, especially in Germany, has also contributed to market stability, pointing to a firm and steady outlook ahead.
The global market of Nicotinamide (Vitamin Bx) has observed a notable recovery in August xxxx after months of bearish sentiment. This uptrend in the market was driven by strategic inventory reassessment and renewed demand across key downstream sectors. The rebound in price index follows a period of oversupply as reported by Vegapharma which is an international association of pharmaceutical businesses. It has reported excessive availability of vitamins including Nicotinamide in previous months which led to a decrease in prices. The Nicotinamide buyers have returned to the market with fresh procurement strategies for new production cycles underway and stockpiles from previous runs being reevaluated. This shift with seasonal anticipation and increased awareness campaigns led by institutions has resulted in a price uptick across major markets.
Key takeaways:
-
The Nicotinamide market rebounded in August after months of bearish trends due to oversupply by strategic inventory reassessment and...
